Abstract
Co-use of opioids (e.g., fentanyl) and stimulants (e.g., methamphetamine; METH) contributed to >30% of the almost 106,000 fatal overdoses in the United States in 2023. Although NarCan® (naloxone) is effective at reversing opioid-induced cardiorespiratory depression, larger and/or more frequent doses are often required for fentanyl and multi-drug overdoses involving fentanyl. Using collar-based pulse oximetry, this study characterized the effects of intravenous (IV) fentanyl (0.0056–0.56 mg/kg), heroin (0.32–5.6 mg/kg), and METH (0.1–1 mg/kg), as well as mixtures of 0.56 mg/kg fentanyl +1 mg/kg METH and 5.6 mg/kg heroin +1 mg/kg METH on blood oxygen saturation (SpO2), heart rate (HR), and breath rate (BR) in male and female Sprague-Dawley rats. To evaluate the potency and effectiveness of naloxone to reverse cardiorespiratory depression, naloxone (0.01–3.2 mg/kg; IV) or vehicle was administered 5 min after opioids or opioid + stimulant mixtures. Naloxone was fully effective at reversing the effects of fentanyl and heroin alone but was more potent for fentanyl. Naloxone was fully effective and equipotent at reversing the cardiorespiratory effects of heroin and heroin + METH but was less potent and less effective at reversing the cardiorespiratory effects of fentanyl + METH compared to fentanyl alone. When administered after fentanyl, heroin, or heroin + METH, naloxone recovered baseline SpO2 in all rats, however, SpO2 was only recovered in 75% of rats treated with fentanyl + METH. These findings suggest that naloxone may be less potent and effective at reversing fentanyl-induced cardiorespiratory depression when METH is co-administered.
1 Introduction
The United States has been battling an opioid epidemic involving multiple waves (e.g., prescription opioids, heroin, fentanyl) for the past 30+ years (; ). Of the almost 106,000 fatal overdoses in the United States in 2023, nearly 70% were attributed to opioids, primarily fentanyl and fentanyl analogues (). However, it is becoming increasingly recognized that the overdose epidemic is now driven by multi-drug overdoses (e.g., fentanyl with stimulant drugs) (; ; ; ). Of the nearly 73,000 synthetic opioid overdose deaths in the United States in 2023, approximately 50% also involved a stimulant (e.g., methamphetamine [METH], cocaine) (National Institute on Drug Abuse, 2024). Cardiorespiratory depression is the primary cause of death for opioid overdoses (White and Irvine, 1999; ), and although there are effective treatments for reversing opioid-induced cardiorespiratory depression (e.g., naloxone; NarCan®), clinical evidence suggests that larger and/or more frequent doses are required for fentanyl and multi-drug overdoses involving fentanyl (Mayer et al., 2018; Pergolizzi Jr et al., 2021a; van Lemmen et al., 2023; ). However, administering larger doses of naloxone also increases risk for adverse cardiorespiratory effects (e.g., tachycardia, tachypnea), which may interact with the cardiovascular effects of stimulants (; Merigian, 1993; ; ; Yugar et al., 2023). Thus, multi-drug overdoses pose a significant public health problem that requires further investigation into the factors (e.g., opioid vs. opioid + stimulant) that might impact the potency and effectiveness of naloxone to safely reverse overdoses involving opioids and stimulants.
Opioid-induced cardiorespiratory depression is mediated by activation of mu opioid receptors (MORs) in brainstem respiratory centers and is characterized by decreased heart rate and ventilation, ultimately resulting in decreased blood oxygenation (i.e., hypoxemia) (; Montandon et al., 2011; Zhang et al., 2011; Liu et al., 2021; ; ). Naloxone reversal of cardiorespiratory depression can precipitate withdrawal at large doses in opioid-dependent individuals or those acutely intoxicated with opioids, which can present as psychological (e.g., irritability, aggression) and physiological (e.g., tachycardia, hypertension, tachypnea) signs and symptoms (; ; Schulteis et al., 1994; Weisshaar et al., 2020; Purssell et al., 2021; Lewter et al., 2022). Many of these adverse effects, including rebound cardiorespiratory responses, are caused by increased norepinephrine levels in the locus coeruleus (; ; ; Nestler et al., 1994; Maldonado, 1997; ). Similarly, amphetamine-type stimulants produce tachycardia and hypertension through indirect activation of noradrenergic receptors (Schindler et al., 1992; ; ; ; Neumann et al., 2023). As such, stimulant involvement in opioid overdoses may exacerbate increases in cardiovascular function commonly observed following reversal of opioid overdoses by naloxone. Case reports also suggest that naloxone reversal of multi-drug overdoses involving opioids and stimulants can result in severe cardiovascular complications (e.g., pulmonary edema, ventricular tachycardia, etc.) (Merigian, 1993; ). Thus, it is important to understand how co-use of opioids and stimulants impacts the potency and effectiveness of naloxone to reverse cardiorespiratory depression.
In addition to challenges posed from the co-involvement of stimulants in opioid overdoses, fentanyl also has unique properties that may further complicate reversal. Fentanyl produces a condition known clinically as “wooden chest syndrome”, which is characterized by rigidity of the intercostal muscles and diaphragm as well as vocal cord closure (; Torralva and Janowsky, 2019; Pergolizzi Jr et al., 2021c; ; ). Preclinical studies have shown that fentanyl-induced chest wall rigidity likely results from MOR-mediated increase in noradrenergic output from the locus coeruleus (; Lui et al., 1989; Lui et al., 1993; Weinger et al., 1989; Weinger et al., 1995; Weinger and Taurek, 1990; Negus et al., 1993; ; Weinger and Bednarczyk, 1994; ; Lee et al., 1995; ). Doses of fentanyl larger than 0.025 mg/kg have also been shown to produce persistent and naloxone-resistant vocal cord closure in rats, whereas a smaller fentanyl dose (0.005 mg/kg) and large morphine dose (5 mg/kg in rats) only produced brief laryngospasm that fully resolved (Miner et al., 2021). Because these potentially naloxone-insensitive effects of fentanyl involve noradrenergic systems they may increase the risk for adverse outcomes (e.g., pulmonary edema, ventricular tachycardia) when stimulants are co-used (; Purssell et al., 2021). Taken together, co-use of fentanyl and METH may decrease the potency and effectiveness of naloxone to safely reverse cardiorespiratory depression and result in sympathomimetic toxicity.
The current study sought to characterize the potency and effectiveness of naloxone to reverse cardiorespiratory depression induced by opioids alone (i.e., fentanyl, heroin) and opioid + stimulant mixtures (i.e., fentanyl + METH, heroin + METH). Collar-based pulse oximetry was used to test the hypotheses that: 1) naloxone will be less potent and/or effective at reversing cardiorespiratory depression from fentanyl than heroin, and 2) naloxone will be equipotent and/or effective at reversing cardiorespiratory depression from heroin alone and a mixture of heroin + METH, but less potent and/or effective at reversing cardiorespiratory depression from a mixture of fentanyl + METH than fentanyl alone.
2 Methods
2.1 Subjects
96 Sprague-Dawley rats (n = 48/sex, 225–250 g upon arrival for females, 275–300 g upon arrival for males) were purchased from Envigo (Indianapolis, IN, United States). Rats were individually housed in a temperature- and humidity-controlled room and maintained on a 14/10-h light/dark cycle. All experiments were conducted during the light cycle at approximately the same time each day. Rats were provided ad libitum access to Purina rat chow and water. All studies were carried out in accordance with the Institutional Animal Care and Use Committees of the University of Texas Health Science Center at San Antonio and the eighth edition of the Guide for Care and Use of Laboratory Animals (National Research Council, 2011).
2.2 Surgery
Rats were anesthetized with 2%–3% isoflurane and prepared with chronic indwelling catheters in the left femoral vein, as previously described (; Seaman and Collins, 2021). Briefly, a trocar was used to tunnel catheters under the skin that attached to a vascular access port placed in the mid-scapular region. Immediately following surgery, rats were administered Excede® (20 mg/kg; SC) or Baytril (10 mg/kg; SC) to prevent infection and meloxicam (1 mg/kg; SC) to minimize pain and discomfort. Rats were allowed 5–7 days to recover and catheters were flushed daily with 0.5 mL of heparinized saline (100 U/mL). During experimentation, catheters were flushed daily with 0.2 mL of saline before and 0.5 mL of heparinized saline after pulse oximetry sessions.
2.3 Drugs
Fentanyl HCl and heroin HCl were generously provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, MD). D-methamphetamine HCl, naloxone HCl and naltrexone HCl were purchased from Sigma-Aldrich (St. Louis, MO, United States). All drugs were dissolved in physiological saline and passed through a 0.2 μm syringe filter prior to administration. For pulse oximetry sessions, all drugs were administered by intravenous (IV) infusion in a volume of 1 mL/kg and flushed with an infusion of 0.5 mL of saline.
2.4 Apparatus
All experiments were conducted in clear small animal enclosures located within ventilated, light- and sound-attenuated chambers (Med Associates, Inc., St. Albans, VT; STARR Life Sciences Corp., Oakmont PA). Each pulse oximetry enclosure was equipped with a swivel mount and lever arm with a low torque slip ring allowing for easy management of tethers and wires. Drug infusions were manually delivered through an infusion tether, which was attached to the pulse oximetry lead. Blood oxygen saturation (SpO2; %), heart rate (HR; beats/min), and breath rate (BR; breaths/min) were continuously recorded using the MouseOx Plus 2.0 Premium Software (STARR Life Sciences Corp., Oakmont PA).
2.5 Pulse oximetry
Prior to each session, rats were briefly anesthetized with 2%–3% isoflurane and an electric shaver was used to remove hair from around the neck, and to secure a pulse oximeter collar sensor around the rat’s neck. Each pulse oximetry session began with a 1-h habituation period, followed by two infusions, 5 minutes apart. After the second infusion, recordings continued for 25 min. Infusion one was saline (0.5 mL), fentanyl (0.0056–0.56 mg/kg), heroin (0.32–5.6 mg/kg), METH (0.1–1 mg/kg), or a mixture of either fentanyl (0.56 mg/kg) + METH (1 mg/kg), or heroin (5.6 mg/kg) + METH (1 mg/kg). Infusion two was either saline or naloxone (0.01–3.2 mg/kg). Each infusion was followed by 0.5 mL saline to ensure all drug was administered. Each data file was timestamped to ensure that the data corresponding to drug infusions could be located. After the session, animals were administered naltrexone (0.32 mg/kg) if SpO2 levels had not returned to ≥90%. The time frame between infusions (i.e., 5 min) was chosen to ensure the maximal effect of fentanyl or heroin on SpO2 would be reached and maintained for at least 1 minute prior to naloxone administration. To reduce the likelihood of tolerance developing to the effects of the opioids, animals were only tested once a week.
2.6 Quantification of data
For agonists alone, the primary dependent variables of cardiorespiratory depression were SpO2, HR, and BR. Opioid doses for antagonist reversal tests were selected based on the capacity to reduce SpO2 to ≥30% of baseline (i.e., saline–saline tests) for at least 30 min. Recovery of baseline SpO2 was defined as averaging 90% SpO2 for at least 5 minutes after the second infusion, with the first minute in the average recorded as the time to recover baseline SpO2. Primary dependent variables for antagonist reversal of cardiorespiratory depression were also SpO2, HR, and BR. Rebound tachycardia and rebound tachypnea were defined as the maximum HR or BR value recorded within 10 min after naloxone infusion minus the average HR or BR values over this same time frame (5–15 min) when the same subject was tested saline for both infusions.
2.7 Data analysis
Time-effect graphs produced from pulse oximetry readings were analyzed using area under the curve (AUC) analysis. Data were calculated for individual subjects and presented as the group mean ± the standard error of the mean (S.E.M.). For agonists alone (i.e., fentanyl-saline, heroin-saline), two-way ANOVAs (factors being opioid dose and sex) were performed to determine any statistically significant differences from baseline (i.e., saline-saline) in cardiorespiratory variables (e.g., SpO2, HR, BR). For antagonist reversal studies, two-way ANOVAs (factors being naloxone dose and sex) were performed to determine any statistically significant differences from baseline in cardiorespiratory variables. For analysis of recovery of baseline SpO2, a multiple logistic regression analysis using a variable slope (four parameters) model was performed to compare the respective opioid alone and opioid + stimulant mixture, with the logEC50 and Hill slope unconstrained and the other two parameters constrained as follows: (1) bottom, constant equal to 0, and (2) top, must be between zero and 100.1. Three-way ANOVAs (factors being opioid condition, naloxone dose, and sex) were also conducted to determine statistically significant differences in naloxone reversal of HR and BR (i.e., rebound tachycardia/tachypnea), and minutes to recovery between the respective opioid alone and opioid + stimulant mixture condition.
3 Results
3.1 Fentanyl and heroin dose-dependently produced cardiorespiratory depression
Time-effect functions were established for fentanyl alone (Figure 1A, left) and heroin alone (Figure 1A, right) on SpO2, HR, and BR. The AUC analyses for the time-effect functions (Figure 1B) demonstrate that heroin produced dose-related decreases in SpO2 (F [3, 30] = 99.97; p < 0.0001), HR (F [3, 30] = 27.84; p < 0.0001), and BR (F [3, 30] = 17.04; p < 0.0001); there were no significant effects of sex, or dose × sex interactions. Post-hoc analyses indicate that 1 mg/kg heroin and 5.6 mg/kg heroin differed significantly from saline for SpO2 (p < 0.0001 for both), HR (p < 0.05 and p < 0.0001, respectively), and BR (p < 0.05 and p < 0.0001, respectively). Fentanyl produced dose-related decreases in SpO2 (F [3, 30] = 161.5; p < 0.0001) and HR (F [3, 30] = 18.45; p < 0.0001), but not BR (F [3, 30] = 1.25; p = 0.31); there were no significant effects of sex, or dose × sex interactions. Post-hoc analyses indicate that 0.056 mg/kg fentanyl and 0.56 mg/kg fentanyl differed significantly from saline for SpO2 (p < 0.0001 for both) and HR (p < 0.01 and p < 0.0001, respectively).
FIGURE 1
3.2 Naloxone reversal of the cardiorespiratory depressant effects of fentanyl and heroin alone
Time-effect functions were established for naloxone (0.01–3.2 mg/kg) reversal of the cardiorespiratory depressant effects of heroin (5.6 mg/kg) alone (Figure 2A, left) and fentanyl (0.56 mg/kg) alone (Figure 3A, left) on SpO2, HR, and BR. The AUC analyses for the time-effect functions (Figure 2B) demonstrate that naloxone dose-dependently reversed the depressant effects of heroin alone on SpO2 (F [5, 60] = 45.77; p < 0.0001), HR (F [5, 60] = 7.49; p < 0.0001), and BR (F [5, 60] = 3.24; p < 0.05); there were no significant effects of sex, or dose × sex interactions. The AUC analyses for the time-effect functions (Figure 3B) demonstrate that naloxone dose-dependently reversed the depressant effects of fentanyl on SpO2 (F [5, 60] = 56.62; p < 0.0001) and HR (F [5, 60] = 4.31; p < 0.01), but not BR (F [5, 60] = 0.76; p = 0.58); there were no significant effects of sex, or dose × sex interactions.
FIGURE 2
FIGURE 3
Recovery of baseline SpO2 from fentanyl (0.56 mg/kg) and heroin (5.6 mg/kg) in the absence of naloxone (i.e., fentanyl-saline, heroin-saline) can be seen in Figures 4A,B, respectively. As shown in Figure 4, naloxone (0.01–3.2 mg/kg) produced dose-related increases in the percentage of animals that met recovery criteria for fentanyl and heroin alone. A multiple logistics regression analysis revealed that one curve could not fit the recovery data for fentanyl and heroin alone (p < 0.05) and that naloxone was more potent at reversing cardiorespiratory depression from fentanyl alone (ED50 = 0.016) than heroin alone (ED50 = 0.13).
FIGURE 4
The time in minutes for animals to recover ≥90% SpO2 when fentanyl (0.56 mg/kg) and heroin (5.6 mg/kg) were followed by saline or naloxone (0.01–3.2 mg/kg) are shown in Table 1. Without naloxone, 0% of animals recovered baseline SpO2 following treatment with 0.56 mg/kg fentanyl or 5.6 mg/kg heroin. A three-way ANOVA for fentanyl alone and heroin alone revealed a main effect of naloxone dose (F [3, 80] = 34.22; p < 0.0001) and sex (F [1, 80] = 4.73; p < 0.05) on time to recovery, with female rats recovering faster and at smaller doses than males. A dose of 3.2 mg/kg naloxone recovered SpO2 within 1–2 min; there were no significant effects of opioid (i.e., fentanyl or heroin) or any interactions.
TABLE 1
| Drug condition and naloxone dose (mg/kg) | Time (mins) to recovery of baseline SpO2 (±S.E.M.) – Proportion of animals that recovered (n of 12) | ||
|---|---|---|---|
| Grouped | Males | Females | |
| Heroin | |||
| 0 | N/A – 0 of 12 | N/A – 0 of 6 | N/A – 0 of 6 |
| 0.01 | 2.00 (0) – 1 of 12 | N/A – 0 of 6 | 2.00 (0) – 1 of 6 |
| 0.1 | 1.20 (0.20) – 5 of 12 | 1.00 (0) – 1 of 6 | 1.25 (0.25) – 4 of 6 |
| 1.0 | 1.25 (0.13) – 12 of 12 | 1.17 (0.17) – 6 of 6 | 1.33 (0.21) – 6 of 6 |
| 3.2 | 1.83 (0.42) – 12 of 12 | 2.33 (0.80) – 6 of 6 | 1.33 (0.21) – 6 of 6 |
| Heroin + METH | |||
| 0 | N/A | N/A | N/A |
| 0.01 | N/A – 0 of 12 | N/A – 0 of 6 | N/A – 0 of 6 |
| 0.1 | 2.67 (0.80) – 6 of 12 | 1.50 (0.50) – 2 of 6 | 3.25 (1.11) – 4 of 6 |
| 1.0 | 3.81 (1.58) −11 of 12 | 6.20 (3.32) – 5 of 6 | 1.3 (0.31) – 6 of 6 |
| 3.2 | 2.58 (1.05) – 12 of 12 | 1.50 (0.22) – 6 of 6 | 3.67 (2.08) – 6 of 6 |
| Fentanyl | |||
| 0 | N/A – 0 of 12 | N/A – 0 of 6 | N/A – 0 of 6 |
| 0.01 | 4.75 (3.09) – 4 of 12 | 2.00 (0) – 1 of 6 | 5.67 (4.18) – 3 of 6 |
| 0.1 | 6.81 (2.45) – 11 of 12 | 10.00 (3.93) – 6 of 6 | 3.00 (1.76) – 5 of 6 |
| 1.0 | 3.46 (1.32) – 11 of 12 | 1.80 (0.37) – 5 of 6 | 4.83 (2.33) – 6 of 6 |
| 3.2 | 1.17 (0.11) – 12 of 12 | 1.00 (0) – 6 of 6 | 1.33 (0.21) – 6 of 6 |
| Fentanyl + METH | |||
| 0 | N/A | N/A | N/A |
| 0.01 | N/A – 0 of 12 | N/A – 0 of 6 | N/A – 0 of |
| 0.1 | 3.00 (1.31) – 8 of 12 | 5.00 (3.51) – 3 of 6 | 1.80 (0.37) – 5 of 6 |
| 1.0 | 1.38 (0.26) – 8 of 12 | 1.00 (0) – 4 of 6 | 1.75 (0.48) – 4 of 6 |
| 3.2 | 1.56 (0.29) – 9 of 12 | 1.75 (0.48) – 4 of 6 | 1.40 (0.40) – 5 of 6 |
Effects of naloxone (0.01–3.2 mg/kg) administration on the time in minutes it took for animals to recover baseline blood oxygen saturation (SpO2) from heroin (5.6 mg/kg), 5.6 mg/kg heroin +1 mg/kg METH, fentanyl (0.56 mg/kg), and 0.56 mg/kg fentanyl +1 mg/kg METH. Data represent the mean (±SEM) and are presented as group average (n = 12) or by sex (n = 6/sex).
3.3 Naloxone reversal of the cardiorespiratory depressant effects of fentanyl or heroin in a mixture with METH
Time-effect functions were established for METH alone (0.01–1 mg/kg) on SpO2, HR, and BR; however, the locomotor stimulant effects of METH resulted in poor signal quality from the pulse oximeter, and thus, a great deal of missing data and large variability for all three endpoints (data not shown). The largest dose of METH (1 mg/kg) was chosen for use in mixtures as it has been previously shown to increase HR and blood pressure (; ). Time-effect functions were then established for naloxone (0.01–3.2 mg/kg) reversal of the cardiorespiratory depressant effects of a mixture of 5.6 mg/kg heroin +1 mg/kg METH (Figure 2A, right) and a mixture of 0.56 mg/kg fentanyl +1 mg/kg METH (Figure 3A, right) on SpO2, HR, and BR. Naloxone reversal of heroin + METH produced dose-related increases in SpO2 (F [5, 60] = 23.82; p < 0.0001), HR (F [5, 60] = 5.13; p < 0.001), and BR (F [5, 60] = 2.72; p < 0.05); there was a small but significant main effect of sex for naloxone reversal of HR (F [1, 60] = 4.08; p < 0.05), with a greater reversal effect observed in males compared to females. Naloxone reversal of fentanyl + METH produced dose-related increases in SpO2 (F [5, 60] = 8.88; p < 0.0001), HR (F [5, 60] = 3.72; p < 0.01), and BR (F [5, 60] = 2.68; p < 0.05); there were no significant effects of sex, or dose × sex interactions.
As shown in Figure 4, naloxone (0.01–3.2 mg/kg) produced dose-related increases in the percentage of animals that met recovery criteria for all opioid alone and opioid + stimulant mixture conditions. Though 100% of rats recovered to ≥90% SpO2 when naloxone was administered after fentanyl alone, heroin alone, and heroin + METH, only 75% of rats recovered baseline SpO2 when naloxone was administered after a mixture of fentanyl + METH. A multiple logistics regression analysis revealed that one curve fits the recovery data for heroin alone and heroin + METH (p = 0.71) and that naloxone was equipotent at reversing cardiorespiratory depression from heroin alone (ED50 = 0.13) and heroin + METH (ED50 = 0.10). A multiple logistics regression analysis revealed that one curve could not fit for the recovery data for fentanyl alone and fentanyl + METH (p < 0.05) and that naloxone was ∼3.6-fold less potent at reversing cardiorespiratory depression from fentanyl + METH (ED50 = 0.044) than fentanyl alone (ED50 = 0.012).
The time in minutes for animals to recover to ≥90% SpO2 for at least 5 minutes after mixtures of fentanyl + METH and heroin + METH were followed by saline or naloxone (0.01–3.2 mg/kg) are shown in Table 1. A three-way ANOVA for heroin alone and heroin + METH revealed a main effect of naloxone dose (F [3, 80] = 54.40; p < 0.0001) and sex (F [1, 80] = 6.54; p < 0.05) on time to recovery, with female rats recovering faster and at smaller doses than males. A dose of 3.2 mg/kg naloxone recovered SpO2 within 2–3 min; there were no significant effects of drug condition (i.e., heroin vs. heroin + METH). A three-way ANOVA for fentanyl alone and fentanyl + METH revealed a main effect of naloxone dose (F [3, 80] = 17.26; p < 0.0001) and drug condition (F [1, 80] = 6.71; p < 0.05) on time to recovery; there was no significant effects of sex or any interactions. At a dose of 3.2 mg/kg naloxone, it took ∼7-fold longer for animals to recover from a mixture of fentanyl + METH (∼7 min) than fentanyl alone (∼1 min).
3.4 Naloxone dose-dependently increased rebound tachycardia and tachypnea from fentanyl and heroin alone and in a mixture with METH
A dose-effect function was established to evaluate the rebound tachycardia (Figure 5A) and tachypnea (Figure 5B) observed following naloxone (0.01–3.2 mg/kg) reversal of cardiorespiratory depression from fentanyl alone and fentanyl + METH (Figure 5, left) and from heroin alone and heroin + METH (Figure 5, right). Three-way ANOVAs for heroin alone and heroin + METH revealed a main effect of naloxone dose (F [3, 80] = 15.60; p < 0.0001) and sex (F [1, 80] = 25.69; p < 0.0001) on rebound tachycardia and of naloxone dose (F [3, 80] = 6.18; p < 0.001) and sex (F [1, 80] = 5.67; p < 0.05) on tachypnea, with male rats exhibiting greater rebound effects on HR and BR than female rats. There were no significant effects of drug condition or any interactions. Three-way ANOVAs for fentanyl alone and fentanyl + METH revealed a main effect of naloxone dose on rebound tachycardia (F [3, 80] = 3.97; p < 0.05) and tachypnea (F [3, 80] = 3.44; p < 0.05); there were no significant effects of sex or drug condition, but there was a significant naloxone dose × drug interaction observed for tachypnea (F [3, 80] = 4.17; p < 0.01).
FIGURE 5
4 Discussion
Overdose deaths involving opioids and stimulants have been increasing for the past 10+ years in the United States. Available evidence suggests that multi-drug overdoses require larger and/or more frequent administration of naloxone, which increases the risk for adverse cardiovascular complications (Merigian, 1993; ; van Lemmen et al., 2023; ). In addition, current treatment strategies are ineffective at safely reversing overdoses involving opioids and stimulants, which may be contributing to annual increases in fatal multi-drug overdoses (). The current study sought to address this knowledge gap by using a collar-based pulse oximetry system that allowed for the continuous and simultaneous recording of cardiorespiratory endpoints (e.g., SpO2, HR, BR) in awake, freely moving rats to determine the potency and effectiveness of naloxone to reverse cardiorespiratory depression from fentanyl and heroin, administered alone and in combination with METH. There were three main findings: 1) naloxone was more potent at reversing fentanyl-than heroin-induced cardiorespiratory depression but fully effective for both opioids, 2) combining METH with heroin did not alter the potency or effectiveness of naloxone to recover cardiorespiratory function, and 3) naloxone was less effective and potent at reversing fentanyl + METH than fentanyl alone. Secondary analyses indicate co-administration of METH with either heroin or fentanyl did not affect the magnitude of the rebound tachycardia or tachypnea associated with naloxone reversal of cardiorespiratory endpoints. In addition, our study did not reveal any major sex differences in the depressant effects of heroin or fentanyl alone, the potency or effectiveness of naloxone to reverse cardiorespiratory depression, or the rebound tachycardia or tachypnea from reversal of the opioids or opioid + stimulant mixtures. Altogether, our data show that naloxone was less potent and effective at reversing the cardiorespiratory effects of a mixture of fentanyl + METH than fentanyl alone, suggesting that current treatment strategies may be ineffective in safely reversing fentanyl-involved multi-drug overdoses.
Although it is well-established that cardiorespiratory depression is the primary cause of fatal opioid overdoses, this study characterized the effects of heroin and fentanyl on SpO2, HR, and BR to identify equieffective doses at producing hypoxemia. Heroin and fentanyl dose-dependently increased the magnitude and duration of cardiorespiratory depression, with 0% of animals spontaneously recovering at the largest dose of heroin (5.6 mg/kg) and fentanyl (0.56 mg/kg). These data indicate that fentanyl is ∼10x more potent than heroin at producing hypoxemia. The doses of heroin and fentanyl assessed for naloxone reversal were chosen based on their ability to decrease SpO2 to a comparable magnitude for the entire 30-min experimental session. Our data further demonstrate that heroin- and fentanyl-induced cardiorespiratory depression were dose-dependently reversed following naloxone (0.01–3.2 mg/kg) administration. Furthermore, naloxone was fully effective at reversing cardiorespiratory depression from heroin and fentanyl but was ∼3-fold more potent for fentanyl than heroin. From our results, it was unexpected that naloxone was more potent for fentanyl than heroin given that clinical reports suggest that larger and more frequent doses of naloxone are often required to reverse overdoses involving fentanyl (van Lemmen et al., 2023; ). However, the dose of the opioid administered cannot be controlled in emergency settings, and blood levels of fentanyl associated with overdose may be significantly larger than those achieved in the present study (Palamalai et al., 2013). Furthermore, overdose patients likely have additional psychoactive substances in their systems (e.g., METH, xylazine) that may not be reported, but can nonetheless complicate reversal or reduce the potency of naloxone in clinical settings (Pergolizzi Jr et al., 2021b; ; ). In addition, the depressant effects of heroin on HR and BR were slightly more prolonged at the largest dose than fentanyl, suggesting that doses of 5.6 mg/kg heroin and 0.56 mg/kg fentanyl might not have been functionally equivalent in terms of their effects on overall cardiorespiratory function which could have also contributed to the slight differences in naloxone potency. Contrary to our results, a study using whole-body plethysmography in rats found that naloxone was equipotent and effective at reversing cardiorespiratory depression from doses of heroin (3.2 mg/kg) and fentanyl (0.1 mg/kg) (). However, it should be noted that the dose of fentanyl was not only smaller than the dose used in our study, but also one of the smaller doses of fentanyl (0.05–0.3 mg/kg) that has previously been shown to produce muscle rigidity in anesthetized and mechanically ventilated rats (Lui et al., 1989; ; ). Furthermore, it has been suggested that these unique properties of fentanyl (e.g., chest wall rigidity, vocal cord closure) may reduce the potency or effectiveness of naloxone to reverse cardiorespiratory depression (Torralva and Janowsky, 2019; Miner et al., 2021) due to the involvement of noradrenergic mechanisms (; Lui et al., 1989; Lui et al., 1993; Weinger et al., 1989; Weinger et al., 1995; Weinger and Bednarczyk, 1994). Taken together, our data do not support our hypothesis that naloxone is less potent and effective at reversing cardiorespiratory depression from fentanyl alone than heroin alone.
Clinical evidence suggests that larger and/or more frequent naloxone doses are required to reverse multi-drug overdoses involving opioids (Van Lemmen et al., 2023; ). In the present study, naloxone was equipotent and fully effective at reversing cardiorespiratory depression from heroin alone and a mixture of heroin + METH. However, when naloxone was evaluated in rats treated with a mixture of fentanyl + METH, it was found to be both less potent and less effective at reversing cardiorespiratory depression as compared to rats treated with fentanyl alone. Whereas naloxone was effective at recovering SpO2 levels in 100% of rats treated with fentanyl, heroin, or heroin + METH, it was only able to recover baseline SpO2 in 75% of rats treated with a mixture of fentanyl + METH. These findings indicate that naloxone was less effective at reversing cardiorespiratory depression from fentanyl when METH was co-administered, which is consistent with studies suggesting a reduced effectiveness of naloxone in treating fentanyl-involved multi-drug overdoses (Pergolizzi Jr et al., 2021b; ). Contrary to our findings, found that METH did not affect the potency or effectiveness of naloxone to reverse cardiorespiratory depression from fentanyl or heroin. However, in addition to using smaller doses of opioid (0.1 mg/kg fentanyl and 3.2 mg/kg heroin) than were used in our study, Hiranita and colleagues only evaluated the effects of naloxone against mixtures of opioids + METH that included a very small dose of 0.1 mg/kg METH that was without effect when tested alone, and smaller than those that have been reported to increase cardiovascular function in rats (; ). Adverse cardiovascular effects of METH (e.g., hypertension, tachycardia) result from a hyperadrenergic state due to increased norepinephrine release from the locus coeruleus, similar to the noradrenergic effects of fentanyl (Schindler et al., 1992; ; Torralva and Janowsky, 2019). In addition, naloxone-precipitated withdrawal can result in increased activity of noradrenergic neurons in the locus coeruleus, which mediates the rebound cardiovascular and respiratory effects (; ; ; Maldonado, 1997). Similar to the doses of fentanyl and METH evaluated by , the authors also administered smaller doses of naloxone (>0.1 mg/kg) than those employed in the current study, which may not have elicited as large of rebound effects as those observed in this study. Taken together, our findings support our hypothesis that naloxone is less potent and effective at reversing cardiorespiratory depression from fentanyl + METH than fentanyl alone.
While it was expected that naloxone would be less potent and effective at reversing cardiorespiratory depression from fentanyl when METH was co-administered, it was unexpected that rebound cardiorespiratory effects were not altered by METH involvement. Clinical data indicate that larger naloxone doses, commonly administered for fentanyl and multi-drug overdoses, increase the risk for cardiovascular complications (Merigian, 1993; ; Yugar et al., 2023). The overlapping effects of fentanyl, METH, and naloxone reversal of cardiorespiratory depression on noradrenergic signaling could contribute to a sympathomimetic toxidrome and explain the cardiovascular consequences (e.g., pulmonary edema, ventricular tachycardia, atrial fibrillation) observed following naloxone reversal of fentanyl-involved multi-drug overdoses (Lui et al., 1989; ; Schindler et al., 1992; Torralva and Janowsky, 2019; Neumann et al., 2023; ). Additionally, co-administration of naloxone with pharmacological treatments that reduce norepinephrine (e.g., α2-adrenergic receptor agonists) may alleviate adverse effects during multi-drug overdoses (e.g., METH-induced agitation) (Tackett et al., 2024). As found in our study, 100% of animals recovered from fentanyl, heroin, and heroin + METH but only 75% of animals recovered from fentanyl + METH. Although our findings support that larger naloxone doses produce greater rebound tachycardia and tachypnea following reversal of cardiorespiratory depression, METH co-administration did not further exacerbate HR or BR. Taken together, our data suggest that rebound tachycardia and tachypnea are not directly responsible for the reduced potency and effectiveness of naloxone to reverse cardiorespiratory depression from fentanyl when combined with METH.
Although a disproportionate number of men suffer from fatal opioid overdoses compared to women (; ; National Institute on Drug Abuse, 2024), this is not necessarily due to sex-related differences in the cardiorespiratory effects of opioids or their reversal by naloxone. Despite other preclinical and clinical studies reporting small sex-related differences in the cardiorespiratory effects of heroin, and sometimes fentanyl (; Overdyk et al., 2014; ; ; ; ; Marchette et al., 2021; Marchette et al., 2023; ; Little and Kosten, 2023), we did not detect any major sex differences in the depressant effects of heroin or fentanyl on SpO2, HR, or BR. There is also mixed evidence to support sex-related differences in naloxone-precipitated and spontaneous withdrawal severity (; Little and Kosten, 2023; ); however, we did not observe any major sex-related differences in the potency and effectiveness of naloxone to reverse the effects of opioids alone, or combined with METH. Our data do suggest that sex-related differences may exist in the potency of naloxone to reverse cardiorespiratory depression, the time to recovery, or the severity of rebound effects under some conditions (e.g., heroin, heroin + METH). However, it is unclear whether these slight differences would translate to meaningful differences in the potency or effectiveness of naloxone to reverse opioid overdoses in people or in the occurrence of adverse effects following naloxone reversal.
Although pulse oximetry provided reliable and continuous measures of SpO2, HR, and BR, reliance on these three endpoints is also a limitation of our study design as they do not capture the full range of cardiorespiratory effects of opioids, stimulants, or the reversal of cardiorespiratory depression by naloxone. However, pulse oximetry was chosen instead of other techniques such as plethysmography or blood gas analysis because it provided a relatively high throughput and non-invasive method for continuously monitoring multiple cardiorespiratory endpoints in awake, freely moving animals. Importantly, the MouseOx® Plus system has been validated against other methods (e.g., co-oximeter, blood gas analyses) and provides accurate measures of SpO2 (Strohl et al., 2007; ). However, further validation studies should be conducted to confirm the accuracy of the MouseOx® Plus system at recording low SpO2 levels (<60%) in both rats and mice. Although reliance on measures of SpO2 limits mechanistic interpretations that could be made with other methods, it provides a clinically-relevant, functional readout of respiratory depression. In addition, our findings show clear tachypnea and tachycardia following naloxone reversal of opioid-induced cardiorespiratory depression, outcomes that are consistent with the literature of adverse effects that can occur during naloxone reversal (; ; ; ). Because our data suggest that co-use of fentanyl and METH may introduce or exacerbate other cardiovascular or respiratory interactions during naloxone reversal of cardiorespiratory depression, future studies will utilize cardiovascular telemetry, electromyography, and/or laryngoscopy to determine the extent to which other physiological endpoints (e.g., hypertension, arrythmia, apnea, chest wall rigidity, vocal cord closure) contribute to the reduced potency and effectiveness of naloxone to reverse fentanyl-induced cardiorespiratory depression when METH is co-administered. Because some of these effects (e.g., chest wall rigidity and vocal cord closure) are thought to be mediated by non-mu-opioid receptors, future studies will evaluate adjunct treatments (e.g., α2-adrenergic receptor agonists, α1-adrenergic receptor antagonists) to probe mechanistic hypotheses and ultimately improve the effectiveness of naloxone to recover cardiorespiratory function following large doses of fentanyl and other commonly co-used drugs, such as METH. In addition, hypoxic brain injury following non-fatal opioid overdose can lead to long-term neurological consequences (e.g., amnesia, cognitive decline) (O’Brien and Todd, 2009; Voronkov et al., 2021; Winstanley et al., 2021; Winstanley et al., 2021; ; Mahoney et al., 2023). As such, future studies will utilize behavioral assays such as rotarod or Barnes maze to assess neurological damage following naloxone reversal of multi-drug overdoses.
In summary, the present data support our hypothesis that naloxone is less potent and effective at reversing cardiorespiratory depression from fentanyl + METH but failed to provide evidence to suggest that METH exacerbates the rebound tachycardia or tachypnea observed following naloxone reversal of fentanyl or heroin. These data suggest that unique properties of fentanyl (e.g., chest wall rigidity) may interact with other rebound effects from naloxone reversal of multi-drug overdoses involving opioids and stimulants to reduce the potency and effectiveness of naloxone to recover normal cardiorespiratory function. Altogether, these findings support the need for the identification and development of treatment strategies to safely and effectively reverse multi-drug overdoses involving fentanyl and stimulants, such as METH.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The animal study was approved by Institutional Animal Care and Use Committees of the University of Texas Health Science Center at San Antonio. The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
JV: Visualization, Writing – review and editing, Data curation, Methodology, Writing – original draft, Formal Analysis, Supervision. RS: Conceptualization, Writing – review and editing, Supervision, Methodology, Formal Analysis, Data curation. DC: Writing – review and editing, Data curation, Visualization, Formal Analysis. GC: Supervision, Writing – review and editing, Investigation, Methodology, Conceptualization, Funding acquisition, Project administration.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This research was supported by National Institutes of Health grants (R01DA039146 (GC) and T32NS082145).
Acknowledgments
The authors would like to thank Yongong Shi, Alexandra Navarro, and Vanessa Rodriguez for their assistance in the completion of these studies. A portion of this work was presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AroraH.OwensS. M.Brooks GentryW. (2001). Intravenous (+)-methamphetamine causes complex dose-dependent physiologic changes in awake rats. Eur. J. Pharmacol.426, 81–87. 10.1016/S0014-2999(01)01202-X
2
BatemanJ. T.SaundersS. E.LevittE. S. (2023). Understanding and countering opioid-induced respiratory depression. Br. J. Pharmacol.180, 813–828. 10.1111/bph.15580
3
BrantJ. M.StringerL.JurkovichL. R.CoombsN. C.MulletteE. J.BuffingtonC.et al (2018). Predictors of oversedation in hospitalized patients. Am. J. Hosp. Pharm.75, 1378–1385. 10.2146/ajhp170558
4
BrentP. J.ChahlL. A. (1991). Effects of naloxone-precipitated withdrawal after a single dose of morphine on catecholamine concentrations in guinea-pig brain. Neurochem. Res.16, 525–531. 10.1007/BF00974870
5
BurgraffN. J.BaertschN. A.RamirezJ.-M. (2023). A comparative examination of morphine and fentanyl: unravelling the differential impacts on breathing and airway stability. J. Physiol.601, 4625–4642. 10.1113/JP285163
6
BuxtonJ. A.GauthierT.KinshellaM.-L. W.GodwinJ. (2018). A 52-year-old man with fentanyl-induced muscle rigidity. Can. Med. Assoc. J.190, E539–E541. 10.1503/cmaj.171468
7
CampbellC.WeingerM. B.QuinnM. (1995). Alterations in diaphragm EMG activity during opiate-induced respiratory depression. Respir. Physiol.100, 107–117. 10.1016/0034-5687(94)00119-K
8
CanoM.JonesA.SilversteinS. M.DaniulaityteR.LoVecchioF. (2025). Naloxone administration and survival in overdoses involving opioids and stimulants: an analysis of law enforcement data from 63 Pennsylvania counties. Int. J. Drug Policy135, 104678–11. 10.1016/j.drugpo.2024.104678
9
CarlsonH. N.SperaA. G.SmithM. A. (2024). Effects of xylazine on naloxone-precipitated fentanyl withdrawal in Male and female rats. Drug Alcohol Depend.264, 112450–112455. 10.1016/j.drugalcdep.2024.112450
10
CavalloD.KellyE.HendersonG.Abdala SheikhA. P. (2023). Comparison of the effects of fentanyls and other μ opioid receptor agonists on the electrical activity of respiratory muscles in the rat. Front. Pharmacol.14, 1277248–21. 10.3389/fphar.2023.1277248
11
ChangA. P.-L.DixonW. R. (1990). Role of plasma catecholamines in eliciting cardiovascular changes seen during naloxone-precipitated withdrawal in conscious, unrestrained morphine-dependent rats. J. Pharmacol. Exp. Ther.254, 857–863. 10.1016/S0022-3565(25)12748-1
12
ChristineP. J.KimmelS. D.MartinS. A.MassadC.WalleyA. Y. (2025). National estimates of opioid overdose hospitalizations resulting in hypoxic-ischemic brain injury. J. Gen. INTERN Med.10.1007/s11606-025-09804-z
13
CiccaroneD. (2021). The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr. Opin. Psychiatry34, 344–350. 10.1097/YCO.0000000000000717
14
CiceroT. J.NockB.MeyerE. R. (2002). Gender-linked differences in the expression of physical dependence in the rat. Pharmacol. Biochem. Behav.72, 691–697. 10.1016/S0091-3057(02)00740-2
15
CruzS. L.Rodrı́guez-ManzoG. (2000). Gender differences in the cardiovascular responses to morphine and naloxone in spinal rats. Eur. J. Pharmacol.397, 121–128. 10.1016/S0014-2999(00)00260-0
16
DahanA.AartsL.SmithT. W. (2010). Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology112, 226–238. 10.1097/ALN.0b013e3181c38c25
17
DahanA.FrankoT. S.CarrollJ. W.CraigD. S.CrowC.GalinkinJ. L.et al (2024). Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Front. Public Health12, 1346109–1346111. 10.3389/fpubh.2024.1346109
18
DoyleM. R.SulimaA.RiceK. C.CollinsG. T. (2021). MDPV self-administration in female rats: influence of reinforcement history. Psychopharmacol. Berl.238, 735–744. 10.1007/s00213-020-05726-2
19
EllisM. S.KasperZ. A.CiceroT. J. (2018). Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend.193, 14–20. 10.1016/j.drugalcdep.2018.08.029
20
FeriaM.AlvarezC.DomínguezJ.SánchezA.BoadaJ. (1990). Naloxone potentiation of cardiovascular responses to sympathomimetic amines in the rat. J. Pharmacol. Exp. Ther.255, 523–528. 10.1016/s0022-3565(25)22978-0
21
FerrucciM.GiorgiF.BartalucciA.BuscetiC.FornaiF. (2013). The effects of locus coeruleus and norepinephrine in methamphetamine toxicity. Curr. Neuropharmacol.11, 80–94. 10.2174/157015913804999522
22
FerrucciM.LimanaqiF.RyskalinL.BiagioniF.BuscetiC. L.FornaiF. (2019). The effects of amphetamine and methamphetamine on the release of norepinephrine, dopamine and acetylcholine from the brainstem reticular Formation. Front. Neuroanat.13, 48–20. 10.3389/fnana.2019.00048
23
FriedmanJ.ShoverC. L. (2023). Charting the fourth wave: geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. Addiction118, 2477–2485. 10.1111/add.16318
24
FriedmanJ.MonteroF.BourgoisP.WahbiR.DyeD.Goodman-MezaD.et al (2022). Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend.233, 109380–109388. 10.1016/j.drugalcdep.2022.109380
25
FuM.-J.LinT. C. Y.LuiP.-W.LeeT.-Y.ChanS. H. H. (1994). Involvement of Goα subtype of guanine nucleotide-binding regulatory protein at the locus coeruleus in fentanyl-induced muscular rigidity in the rat. Neurosci. Lett.165, 199–202. 10.1016/0304-3940(94)90744-7
26
GambleJ. (2016). Comparison of starr life Sciences’ MouseOx® Plus and Kent Scientifics’ MouseSTAT® pulse oximeters.
27
GarrettJ.VanstonA.OgolaG.GracaB. daCassityC.KouznetsovaM. A.et al (2021). Predicting opioid-induced oversedation in hospitalised patients: a multicentre observational study. BMJ Open11, e051663–e051669. 10.1136/bmjopen-2021-051663
28
HaileC. N.BakerM. D.SanchezS. A.Lopez ArteagaC. A.DuddupudiA. L.CunyG. D.et al (2022). An immunconjugate vaccine alters distribution and reduces the antinociceptive, behavioral and physiological effects of fentanyl in Male and female rats. Pharmaceutics14, 2290–18. 10.3390/pharmaceutics14112290
29
HanY.YanW.ZhengY.KhanM. Z.YuanK.LuL. (2019). The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl. Psychiatry9, 282–289. 10.1038/s41398-019-0625-0
30
HaouziP.TubbsN. (2022). Effects of fentanyl overdose-induced muscle rigidity and dexmedetomidine on respiratory mechanics and pulmonary gas exchange in sedated rats. J. Appl. Physiol.132, 1407–1422. 10.1152/japplphysiol.00819.2021
31
HassanS. F.ZumutS.BurkeP. G.McMullanS.CornishJ. L.GoodchildA. K. (2015). Comparison of noradrenaline, dopamine and serotonin in mediating the tachycardic and thermogenic effects of methamphetamine in the ventral medial prefrontal cortex. Neuroscience295, 209–220. 10.1016/j.neuroscience.2015.03.028
32
HassanS. F.WearneT. A.CornishJ. L.GoodchildA. K. (2016). Effects of acute and chronic systemic methamphetamine on respiratory, cardiovascular and metabolic function, and cardiorespiratory reflexes. J. Physiol.594, 763–780. 10.1113/JP271257
33
HedegaardH.MiniñoA. M.WarnerM. (2020). Drug overdose deaths in the United States, 1999–2019. NCHS Data Brief, no. 394. Hyattsville, MD: National Center for Health Statistics. 10.15620/cdc/170565
34
HeishmanS. J.StitzerM. L.BigelowG. E.LiebsonI. A. (1989). Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure. J. Pharmacol. Exp. Ther.248, 127–134. 10.1016/s0022-3565(25)23620-5
35
HerzigS. J.StefanM. S.PekowP. S.ShiehM.-S.SoaresW.RaghunathanK.et al (2020). Risk factors for severe opioid-related adverse events in a national cohort of medical hospitalizations. J. Gen. Intern. Med.35, 538–545. 10.1007/s11606-019-05490-w
36
HiranitaT.HoN. P.FranceC. P. (2023). Ventilatory effects of fentanyl, heroin, and d -methamphetamine, alone and in mixtures, in Male rats breathing normal air. J. Pharmacol. Exp. Ther.388, 244–256. 10.1124/jpet.123.001653
37
HoopsickR. A.HomishG. G.LeonardK. E. (2021). Differences in opioid overdose mortality rates among middle-aged adults by race/ethnicity and sex, 1999-2018. Public Health Rep.136, 192–200. 10.1177/0033354920968806
38
HunterR. (2005). Ventricular tachycardia following naloxone administration in an illicit drug misuse. J. Clin. Forensic Med.12, 218–219. 10.1016/j.jcfm.2005.01.011
39
JerussiT. P.CapacchioneJ. F.BenvengaM. J. (1987). Reversal of opioid-induced muscular rigidity in rats: evidence for alpha-2 adrenergic involvement. Pharmacol. Biochem. Behav.28, 283–289. 10.1016/0091-3057(87)90226-7
40
JonesC. M.BekheetF.ParkJ. N.AlexanderG. C. (2020). The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol. Rev.42, 154–166. 10.1093/epirev/mxaa011
41
KanofP. D.HandelsmanL.AronsonM. J.NessR.CochraneK. J.RubinsteinK. J. (1992). Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J. Pharmacol. Exp. Ther.260, 355–363. 10.1016/s0022-3565(25)11239-1
42
KaplovitchE.GomesT.CamachoX.DhallaI. A.MamdaniM. M.JuurlinkD. N. (2015). Sex differences in dose escalation and overdose death during chronic opioid therapy: a population-based cohort Study. PLOS ONE10, e0134550. 10.1371/journal.pone.0134550
43
KhannaA. K.BergeseS. D.JungquistC. R.MorimatsuH.UezonoS.LeeS.et al (2020). Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. Anesth. Analg.131, 1012–1024. 10.1213/ANE.0000000000004788
44
KiyatkinE. A.ChoiS. (2024). Brain oxygen responses induced by opioids: focus on heroin, fentanyl, and their adulterants. Front. Psychiatry15, 1354722–16. 10.3389/fpsyt.2024.1354722
45
KwokC. H. T.HardingE. K.BurmaN. E.MarkovicT.MassalyN.van den HoogenN. J.et al (2024). Pannexin-1 channel inhibition alleviates opioid withdrawal in rodents by modulating locus coeruleus to spinal cord circuitry. Nat. Commun.15, 6264–17. 10.1038/s41467-024-50657-7
46
LalleyP. M. (2003). Mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances. Am. J. Physiol. Regul. Integr. Comp. Physiol.285, R1287–R1304. 10.1152/ajpregu.00199.2003
47
LameijerH.AziziN.LigtenbergJ. J. M.Ter MaatenJ. C. (2014). Ventricular tachycardia after naloxone administration: a drug related complication? Case report and literature review. Drug Saf. Case Rep.1, 2–4. 10.1007/s40800-014-0002-0
48
LeeT. Y.FuM. J.LuiP. W.ChanS. H. (1995). Involvement of potassium and calcium channels at the locus coeruleus in fentanyl-induced muscular rigidity in the rat. Neurosci. Lett.199, 195–198. 10.1016/0304-3940(95)12049-a
49
LewterL. A.JohnsonM. C.TreatA. C.KassickA. J.AverickS.KolberB. J. (2022). Slow-sustained delivery of naloxone reduces typical naloxone-induced precipitated opioid withdrawal effects in male morphine-dependent mice. J. Neurosci. Res.100, 339–352. 10.1002/jnr.24627
50
LittleK. M.KostenT. A. (2023). Focus on fentanyl in females: sex and gender differences in the physiological and behavioral effects of fentanyl. Front. Neuroendocrinol.71, 101096–11. 10.1016/j.yfrne.2023.101096
51
LiuS.KimD.-I.OhT. G.PaoG. M.KimJ.-H.PalmiterR. D.et al (2021). Neural basis of opioid-induced respiratory depression and its rescue. Proc. Natl. Acad. Sci. U.S.A.118, e2022134118–e2022134119. 10.1073/pnas.2022134118
52
LuiP. W.LeeT. Y.ChanS. H. (1989). Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Neurosci. Lett.96, 114–119. 10.1016/0304-3940(89)90252-8
53
LuiP.-W.ChangG.-J.LeeT.-Y.ChanS. H. H. (1993). Antagonization of fentanyl-induced muscular rigidity by denervation of the coerulospinal noradrenergic pathway in the rat. Neurosci. Lett.157, 145–148. 10.1016/0304-3940(93)90723-X
54
MahoneyJ. J.WinstanleyE. L.CastilloF.LubaR.MartonJ.AlschulerD. M.et al (2023). A pilot study investigating cognitive impairment associated with opioid overdose. Drug Alcohol Dependence247, 109865. 10.1016/j.drugalcdep.2023.109865
55
MaldonadoR. (1997). Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev.21, 91–104. 10.1016/0149-7634(95)00061-5
56
MarchetteR. C. N.Gregory-FloresA.TunstallB. J.CarlsonE. R.JacksonS. N.SulimaA.et al (2021). κ-Opioid receptor antagonism reverses heroin withdrawal-induced hyperalgesia in male and female rats. Neurobiol. Stress14, 100325–11. 10.1016/j.ynstr.2021.100325
57
MarchetteR. C. N.CarlsonE. R.FryeE. V.HastingsL. E.VendruscoloJ. C. M.Mejias-TorresG.et al (2023). Heroin- and fentanyl-induced respiratory depression in a rat plethysmography model: potency, tolerance, and sex differences. J. Pharmacol. Exp. Ther.385, 117–134. 10.1124/jpet.122.001476
58
MayerS.BoydJ.CollinsA.KennedyM. C.FairbairnN.McNeilR. (2018). Characterizing fentanyl-related overdoses and implications for overdose response: findings from a rapid ethnographic study in Vancouver, Canada. Drug Alcohol Depend.193, 69–74. 10.1016/j.drugalcdep.2018.09.006
59
MerigianK. S. (1993). Cocaine-induced ventricular arrhythmias and rapid atrial fibrillation temporally related to naloxone administration. Am. J. Emerg. Med.11, 96–97. 10.1016/0735-6757(93)90074-l
60
MinerN. B.SchutzerW. E.ZarnegarniaY.JanowskyA.TorralvaR. (2021). Fentanyl causes naloxone-resistant vocal cord closure: a platform for testing opioid overdose treatments. Drug Alcohol Depend.227, 108974–108975. 10.1016/j.drugalcdep.2021.108974
61
MontandonG.QinW.LiuH.RenJ.GreerJ. J.HornerR. L. (2011). PreBotzinger complex neurokinin-1 receptor-expressing neurons mediate opioid-induced respiratory depression. J. Neurosci.31, 1292–1301. 10.1523/JNEUROSCI.4611-10.2011
62
National Institute on Drug Abuse (2024). Drug overdose death rates. Rockville, MD: National Institute on Drug Abuse (NIDA). Available online at: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates (Accessed May 27, 2024).
63
National Research Council (2011). Guide for the care and use of laboratory animals. 8th Edn. Washington, DC: National Academies Press. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK54050/ (Accessed September 15, 2025).
64
NegusS. S.PasternakG. W.KoobG. F.WeingerM. B. (1993). Antagonist effects of beta-funaltrexamine and naloxonazine on alfentanil-induced antinociception and muscle rigidity in the rat. J. Pharmacol. Exp. Ther.264, 739–745. 10.1016/s0022-3565(25)10202-4
65
NestlerE. J.AlrejaM.AghajanianG. K. (1994). Molecular and cellular mechanisms of opiate action: studies in the rat locus coeruleus. Brain Res. Bull.35, 521–528. 10.1016/0361-9230(94)90166-X
66
NeumannJ.HußlerW.AzatsianK.HofmannB.GergsU. (2023). Methamphetamine increases force of contraction in isolated human atrial preparations through the release of noradrenaline. Toxicol. Lett.383, 112–120. 10.1016/j.toxlet.2023.06.012
67
OverdykF.DahanA.RoozekransM.SchrierR. van derAartsL.NiestersM. (2014). Opioid-Induced respiratory depression in the acute care setting: a compendium of case reports. Pain Manag.4, 317–325. 10.2217/pmt.14.19
68
O’BrienP.ToddJ. (2009). Hypoxic brain injury following heroin Overdose. Brain Impair.10, 169–179. 10.1375/brim.10.2.169
69
PalamalaiV.OlsonK. N.KlossJ.MiddletonO.MillsK.StroblA. Q.et al (2013). Superiority of postmortem liver fentanyl concentrations over peripheral blood influenced by postmortem interval for determination of fentanyl toxicity. Clin. Biochem.46, 598–602. 10.1016/j.clinbiochem.2013.02.001
70
Pergolizzi JrJ. V.DahanA.Ann LeQuangJ.RaffaR. B. (2021a). Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. J. Clin. Pharm. Ther.46, 1501–1504. 10.1111/jcpt.13462
71
Pergolizzi JrJ. V.VarrassiG.LeQuangJ. A.RaffaR. B. (2021b). The challenge of polysubstance use overdose. Open J. Soc. Sci.9, 529–542. 10.4236/jss.2021.97038
72
Pergolizzi JrJ. V.WebsterL. R.VortsmanE.Ann LeQuangJ.RaffaR. B. (2021c). Wooden Chest syndrome: the atypical pharmacology of fentanyl overdose. J. Clin. Pharm. Ther.46, 1505–1508. 10.1111/jcpt.13484
73
PurssellR.GodwinJ.MoeJ.BuxtonJ.CrabtreeA.KestlerA.et al (2021). Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study. Clin. Toxicol. (Phila)59, 38–46. 10.1080/15563650.2020.1758325
74
SchindlerC. W.ZhengJ.-W.TellaS. R.GoldbergS. R. (1992). Pharmacological mechanisms in the cardiovascular effects of methamphetamine in conscious squirrel monkeys. Pharmacol. Biochem. Behav.42, 791–796. 10.1016/0091-3057(92)90031-A
75
SchulteisG.MarkouA.GoldL. H.StinusL.KoobG. F. (1994). Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J. Pharmacol. Exp. Ther.271, 1391–1398. 10.1016/s0022-3565(25)24024-1
76
SeamanR. W.CollinsG. T. (2021). Impact of morphine dependence and withdrawal on the reinforcing effectiveness of fentanyl, cocaine, and methamphetamine in rats. Front. Pharmacol.12, 691700–691708. 10.3389/fphar.2021.691700
77
StrohlK. P.BaekeyD.DaseS.HeteB. (2007). MouseOx® validation Paper | STARR life sciences. Starr. Available online at: https://www.starrlifesciences.com/resource/mouseox-validation-paper/ (Accessed August 18, 2025).
78
TackettW. R.YalakalaJ.HambuchenM. D. (2024). Co-administration of naloxone and dexmedetomidine to simultaneously reverse acute effects of fentanyl and methamphetamine in rats. Drug Alcohol Depend.259, 111301–111307. 10.1016/j.drugalcdep.2024.111301
79
TorralvaR.JanowskyA. (2019). Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis. J. Pharmacol. Exp. Ther.371, 453–475. 10.1124/jpet.119.258566
80
van LemmenM.FlorianJ.LiZ.van VelzenM.van DorpE.NiestersM.et al (2023). Opioid overdose: limitations in naloxone reversal of respiratory depression and prevention of cardiac arrest. Anesthesiology139, 342–353. 10.1097/ALN.0000000000004622
81
VoronkovM.AtaiantsJ.CocchiaroB.StockJ. B.LankenauS. E. (2021). A vicious cycle of neuropathological, cognitive and behavioural sequelae of repeated opioid overdose. Int. J. Drug Policy97, 103362. 10.1016/j.drugpo.2021.103362
82
WeingerM. B.BednarczykJ. M. (1994). Atipamezole, an alpha 2 antagonist, augments opiate-induced muscle rigidity in the rat. Pharmacol. Biochem. Behav.49, 523–529. 10.1016/0091-3057(94)90064-7
83
WeingerM. B.TaurekD. L. (1990). The effects on muscle tone of selective alpha-2 adrenergic agonists and antagonists during high-dose alfentanil anesthesia in the rat. Anesth. Analg.70, S425. 10.1213/00000539-199002001-00425
84
WeingerM. B.SegalI. S.MazeM. (1989). Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat. Anesthesiology71, 242–249. 10.1097/00000542-198908000-00013
85
WeingerM. B.ChenD.-Y.LinT.LauC.KoobG. F.SmithN. T. (1995). A role for CNS α-2 adrenergic receptors in opiate-induced muscle rigidity in the rat. Brain Res.669, 10–18. 10.1016/0006-8993(94)01216-5
86
WeisshaarS.BrandtL.LitschauerB.Sheik‐RezaeiS.MoserL.NirnbergerG.et al (2020). Dose‐dependent naloxone‐induced morphine withdrawal symptoms in opioid‐dependent males—a double‐blinded, randomized study. Br. J. Clin. Pharmacol.86, 1610–1619. 10.1111/bcp.14271
87
WhiteJ. M.IrvineR. J. (1999). Mechanisms of fatal opioid overdose. Addiction94, 961–972. 10.1046/j.1360-0443.1999.9479612.x
88
WinstanleyE. L.MahoneyJ. J.CastilloF.ComerS. D. (2021). Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: a systematic review. Drug Alcohol Depend.226, 108838. 10.1016/j.drugalcdep.2021.108838
89
YugarB.McManusK.RamdinC.NelsonL. S.ParrisM. A. (2023). Systematic review of naloxone dosing and adverse events in the emergency department. J. Emerg. Med.65, e188–e198. 10.1016/j.jemermed.2023.05.006
90
ZhangZ.ZhuangJ.ZhangC.XuF. (2011). Activation of opioid μ-receptors in the commissural subdivision of the nucleus tractus solitarius abolishes the ventilatory response to hypoxia in anesthetized rats. Anesthesiology115, 353–363. 10.1097/ALN.0b013e318224cc1f
Summary
Keywords
polysubstance abuse, opioids, stimulants, naloxone, pulse oximetry
Citation
Vazquez JM, Seaman Jr. RW, Caldron D and Collins GT (2025) Naloxone reversal of the cardiorespiratory depressant effects of opioids and mixtures of opioids and stimulants in rats. Front. Pharmacol. 16:1654791. doi: 10.3389/fphar.2025.1654791
Received
26 June 2025
Accepted
10 September 2025
Published
22 September 2025
Volume
16 - 2025
Edited by
Lori A. Knackstedt, University of Florida, United States
Reviewed by
Lin Piao, University of Chicago Medicine, United States
Willard Sharp, The University of Chicago, United States
Updates
Copyright
© 2025 Vazquez, Seaman, Caldron and Collins.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gregory T. Collins, collinsg@uthscsa.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.